We are live on ! Find out more
RLYB icon

Rallybio

38 hedge funds and large institutions have $41.9M invested in Rallybio in 2026 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 7 increasing their positions, 17 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

299% more capital inflows, than outflows

Capital inflows: $15.5M | Capital outflows: $3.89M

29.2% more ownership

Funds ownership: 59.02% → 88.22% (+29%)

17% less funds holding

Funds holding: 46 → 38 (-8)

35% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 20

59% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 17

67% less funds holding in top 10

Funds holding in top 10: 3 → 1 (-2)

Holders
38
Holders Change
-8
Holders Change %
-17.39%
% of All Funds
0.46%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.01%
New
13
Increased
7
Reduced
17
Closed
20
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

RLYB Hedge Fund Activity: Q1 2026 in Review

38 of the 8,242 institutional investors tracked by Wall St. Rank reported a position in Rallybio (RLYB) for Q1 2026, worth a combined $41.9M — up 145% from $17.1M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of RLYB and 13 opened new positions — a net loss of 7 holders — while 17 trimmed existing stakes and 7 added.

The largest buyer was Fidelity Investments, adding an estimated $3.98M. The largest seller was Johnson & Johnson, cutting an estimated $2.06M.

  • 38 institutional investors held Rallybio (RLYB) as of Q1 2026, down from 46 in Q4 2025.
  • Funds reported $41.9M of Rallybio stock for Q1 2026, up 145% quarter-over-quarter.
  • 13 funds opened new Rallybio positions in Q1 2026 and 20 closed out, a net change of -7 holders.
  • The largest Rallybio buyer in Q1 2026 was Fidelity Investments, an estimated $3.98M added.
  • The largest Rallybio seller in Q1 2026 was Johnson & Johnson, an estimated $2.06M sold.

Based on aggregated 13F filings for Q1 2026.